Free tool
FAERS Monitor: Myleran
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 009386 or its brand name (Myleran, Busulfan). Reports on generic versions are filed under their own applications.
Reports
15,920
Serious
15,144
95% of reports
Hospitalization
3,297
Death reported
4,660
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use2,098
- product use in unapproved indication1,727
- mucosal inflammation1,121
- drug ineffective1,088
- graft versus host disease922
- venoocclusive liver disease888
- febrile neutropenia886
- cytomegalovirus infection881
- acute graft versus host disease832
- pyrexia827
- chronic graft versus host disease645
- cytomegalovirus infection reactivation619
- acute graft versus host disease in skin599
- thrombocytopenia577
- infection556
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 112 |
| 2005 | 139 |
| 2006 | 83 |
| 2007 | 101 |
| 2008 | 224 |
| 2009 | 154 |
| 2010 | 212 |
| 2011 | 603 |
| 2012 | 441 |
| 2013 | 291 |
| 2014 | 504 |
| 2015 | 357 |
| 2016 | 446 |
| 2017 | 716 |
| 2018 | 1,123 |
| 2019 | 1,410 |
| 2020 | 1,532 |
| 2021 | 1,397 |
| 2022 | 1,176 |
| 2023 | 1,067 |
| 2024 | 1,437 |
| 2025 | 1,475 |
| 2026 | 919 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,239 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute graft versus host disease in skinSignal | 599 | 365.1 | 334.0 | 170,160 |
| acute graft versus host diseaseSignal | 832 | 293.2 | 272.4 | 198,089 |
| venoocclusive liver diseaseSignal | 888 | 289.4 | 269.6 | 209,173 |
| chronic graft versus host diseaseSignal | 645 | 287.1 | 264.0 | 150,857 |
| cytomegalovirus infection reactivationSignal | 619 | 215.1 | 197.9 | 113,284 |
| graft versus host diseaseSignal | 922 | 194.1 | 181.5 | 154,350 |
| cytomegalovirus infectionSignal | 881 | 73.9 | 69.2 | 59,972 |
| mucosal inflammationSignal | 1,121 | 59.1 | 55.7 | 61,259 |
| febrile neutropeniaSignal | 886 | 17.9 | 16.8 | 13,951 |
| product use in unapproved indicationSignal | 1,727 | 9.3 | 8.9 | 12,785 |
| thrombocytopeniaSignal | 577 | 6.8 | 6.3 | 2,876 |
| infectionSignal | 556 | 5.1 | 4.7 | 1,829 |
| off label useSignal | 2,098 | 3.2 | 3.0 | 3,243 |
| pyrexiaSignal | 827 | 3.2 | 3.0 | 1,238 |
| drug ineffective | 1,088 | 1.1 | 1.0 | 9 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.